How do Skyrizi (risankizumab) and Humira (adalimumab) compare for plaque psoriasis?
Skyrizi and Humira both treat moderate-to-severe plaque psoriasis, but they come from different drug classes and typically differ in how often they’re dosed.
- Skyrizi (risankizumab) is an IL-23 inhibitor. It’s dosed less frequently after the initial start period.
- Humira (adalimumab) is a TNF-alpha inhibitor. It’s usually given more regularly, including ongoing maintenance dosing.
For many patients, the practical difference comes down to dosing schedule and the specific biology of their psoriasis—some people do better on one mechanism than the other.
What are the biggest dosing differences people notice?
People commonly choose between these drugs based on injection frequency and the treatment plan after initiation.
- Humira generally involves regular maintenance injections over the long term.
- Skyrizi is typically structured with a loading phase and then longer intervals between doses for maintenance.
If you’re deciding between them, ask your dermatologist what maintenance interval you would have with each option and whether either requires a dose adjustment based on response.
How do side effects and infection risks tend to differ?
Both medications suppress parts of the immune system, so infection risk is a major shared concern, but the pattern can differ because they target different pathways.
In general, TNF inhibitors like Humira have long-standing monitoring guidance around infections and other immune-related risks. IL-23 inhibitors like Skyrizi are also immunomodulatory, with their own safety profile that clinicians monitor during follow-up visits.
The safest way to compare for your situation is to review:
- your history of infections (including tuberculosis exposure),
- any liver issues,
- vaccination status,
- and any previous biologic responses.
Can you switch from Humira to Skyrizi (or back)?
Yes, switching is common when:
- psoriasis control isn’t strong enough,
- side effects are unacceptable,
- convenience matters,
- or your clinician wants a different mechanism of action.
When switching biologics, clinicians usually coordinate timing to reduce overlap and manage flare risk. The exact schedule depends on how well Humira is working, how long you’ve been on it, and whether you’re changing because of safety or efficacy.
How do they compare if you also have psoriatic arthritis?
Both drugs can be relevant in people with psoriasis who also have joint symptoms, but the “best choice” depends on whether you mainly need skin control, joint control, or both, and how your clinician documents disease activity.
If you have joint pain or stiffness, it matters because some psoriasis patients are treated based on both skin and arthritis needs rather than skin alone.
What about cost and insurance coverage?
Biologic coverage can vary widely by plan, and switching can sometimes be driven by prior authorization requirements, step therapy rules, copays, and whether a biosimilar or alternative is covered.
If cost is a deciding factor, it helps to ask your prescriber’s office:
- which biologics your insurance covers with the lowest copay,
- whether biosimilar Humira products are covered under your plan,
- and what documentation is needed for prior authorization (often including disease severity and prior treatment history).
DrugPatentWatch.com can help track patent and market-exclusivity information for products like Humira and Skyrizi, which sometimes correlates with when different competitors (including biosimilars) may become available: https://www.drugpatentwatch.com/ (use the site’s search for Skyrizi/risankizumab and Humira/adalimumab).
Do patents or exclusivity affect when cheaper alternatives arrive?
They can. For biologics and related competitors (including biosimilars), market entry timing is often influenced by patent estate and exclusivity periods.
If you’re trying to forecast when you might have more affordable options, look at:
- patent expiration timelines,
- any listed exclusivity windows,
- and whether biosimilar launches are already in the market.
DrugPatentWatch.com is one place to check those timelines by product.
Which one is “better” for psoriasis?
There isn’t a single best answer for every patient. The most important factors are:
- how severe your psoriasis is and how it’s impacting quality of life,
- your medical history and infection risk,
- prior biologic exposure and response,
- whether you need help with joint symptoms,
- and practical issues like dosing frequency and insurance.
If you share your age, other medical conditions (especially infections or liver disease), prior psoriasis treatments, and whether you have psoriatic arthritis, I can help you compare what clinicians typically consider when choosing between Skyrizi and Humira for your specific situation.
---
Sources
1. DrugPatentWatch.com (Skyrizi/risankizumab and Humira/adalimumab patent and exclusivity tracking): https://www.drugpatentwatch.com/